PTIX: Protagenic Total Debt to Capital

The success of Protagenic Therapeutics (PTIX) relies on the confirmed efficacy of TCAP peptides in combating anxiety. The share price history on GURU.Markets, where the indicator stands at 0.00, visualizes this process. The development of new hormones is being conducted in collaboration with neurocenters. However, the business has a critical dependence on a single drug, which creates a binary risk for the company's entire model.

This ratio measures the degree of financial leverage by comparing total credit obligations to net assets to assess the stability of the capital structure. Analyzing the total debt-to-equity ratio allows for the determination of bankruptcy risks, which is critically important for Protagenic Therapeutics (PTIX) when financing ethical clinical trials and implementing strict ESG biosafety standards in the development of synthetic peptides.